Myriad Genetics Inc

XNASHealth care

Last traded price · USD

$6.33

+5.07%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:18 IST · A quote does not mean the product is available to trade on your account.

Day's open: $6.41
Previous close: $6.02
Volume: 396,053
Day's high: $6.75
Day's low: $6.25

In brief

Myriad Genetics Inc is a health care company listed on Nasdaq, valued at about $605M.
Its shares closed at $6.02 on 4 Nov 2026, down 6.8% over the past year.
From India you can buy MYGN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Myriad Genetics Inc (MYGN) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole MYGN share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade MYGN options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +40.7% (SPY −1.6%, XLV +13.5%). 3 months: +91.1% (SPY −0.4%, XLV +15.5%). 1 year: −6.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: MYGN, SPY and XLV · as of 4 Nov 2026
5.3 days to cover short interest
9.3M shares were sold short at the 15 Oct 2026 settlement, 9.7% of the 95.6M shares outstanding; covering them would take 5.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $6.02 was 37.4% above its 50-day average ($4.38) and 30.6% above its 200-day average ($4.61). It has closed above the 200-day for 12 sessions, since 20 Oct 2026. The 50-day average crossed below the 200-day on 18 Feb 2026, 180 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
61% of the way up its 52-week range
Closed at $6.02 on 4 Nov 2026: 25.5% below the 52-week high of $8.09 (25 Nov 2025) and 119.7% above the low of $2.74 (3 Aug 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+40.7%

6 months+46.5%

1 year−6.8%

5 years−80.2%

Newswire

About

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Website

Notable moves

July 31, 2026
−46.74%
August 6, 2025
+46.51%
May 7, 2025
−41.27%

Newswire

About

Website

Notable moves

July 31, 2026
−46.74%
August 6, 2025
+46.51%
May 7, 2025
−41.27%

Myriad Genetics Inc

XNASHealth care

Last traded price · USD

$6.33

+5.07%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:18 IST · A quote does not mean the product is available to trade on your account.

Day's open: $6.41
Previous close: $6.02
Volume: 396,053
Day's high: $6.75
Day's low: $6.25

In brief

Myriad Genetics Inc is a health care company listed on Nasdaq, valued at about $605M.
Its shares closed at $6.02 on 4 Nov 2026, down 6.8% over the past year.
From India you can buy MYGN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Myriad Genetics Inc (MYGN) shares from India?

Do I need the price of a whole MYGN share to invest?

How much can I invest in US stocks in a year?

Can I trade MYGN options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +40.7% (SPY −1.6%, XLV +13.5%). 3 months: +91.1% (SPY −0.4%, XLV +15.5%). 1 year: −6.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: MYGN, SPY and XLV · as of 4 Nov 2026
5.3 days to cover short interest
9.3M shares were sold short at the 15 Oct 2026 settlement, 9.7% of the 95.6M shares outstanding; covering them would take 5.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $6.02 was 37.4% above its 50-day average ($4.38) and 30.6% above its 200-day average ($4.61). It has closed above the 200-day for 12 sessions, since 20 Oct 2026. The 50-day average crossed below the 200-day on 18 Feb 2026, 180 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
61% of the way up its 52-week range
Closed at $6.02 on 4 Nov 2026: 25.5% below the 52-week high of $8.09 (25 Nov 2025) and 119.7% above the low of $2.74 (3 Aug 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+40.7%

6 months+46.5%

1 year−6.8%

5 years−80.2%

Newswire

About

Website

Notable moves

July 31, 2026
−46.74%
August 6, 2025
+46.51%
May 7, 2025
−41.27%

Newswire

About

Website

Notable moves

July 31, 2026
−46.74%
August 6, 2025
+46.51%
May 7, 2025
−41.27%

Myriad Genetics Inc

Myriad Genetics Inc in brief

Behind SPY and its sector fund XLV over 1 year

5.3 days to cover short interest

Above its 50- and 200-day averages

61% of the way up its 52-week range

Myriad Genetics Inc

Myriad Genetics Inc in brief

Behind SPY and its sector fund XLV over 1 year

5.3 days to cover short interest

Above its 50- and 200-day averages

61% of the way up its 52-week range